Agomab Therapeutics NV

Agomab Therapeutics NV(AGMB)資訊與事件

$13.170

-0.637 (-4.84%)收盤時

AGMB 資訊

AGMB 事件

6/29 16:00

Agomab Therapeutics NV Trading Halted Due to Volatility Trading Pause

Agomab Therapeutics NV trading halted, volatility trading pause

6/23 16:30

Agomab Initiates Phase 2b NOV-ERA Study for FSCD Treatment

Agomab announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted small molecule inhibitor of ALK5 for the potential treatment of Fibrostenosing Crohn's Disease, or FSCD. The company has aligned with the FDA on the study design of NOV-ERA, including the study's primary efficacy endpoint of endoscopic passability at Week 24 as assessed by the SES-CD narrowing score, as well as several secondary efficacy endpoints relevant to patients with FSCD. The protocol has been submitted to the FDA and has cleared central Institutional Review Board approval in the U.S. In addition, the study has received approval by Health Canada. The company has also submitted Clinical Trial Applications in multiple countries globally, including in the European Union and Asia Pacific territories. The company expects to initiate the NOV-ERA study following receipt of applicable regulatory and ethics approvals and plans to dose the first participants in the second half of 2026. The planned NOV-ERA study is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2b trial to assess the efficacy and safety of ontunisertib in participants diagnosed with symptomatic FSCD. The trial is expected to enroll up to 320 adult patients globally. To be eligible for the trial, participants must have at least one naive or anastomotic endoscopically non-passable ileal stricture, confirmed by a centrally read Simple Endoscopic Score for Crohn's Disease. Upon study initiation, participants will be randomized in a 1:1:1:1 ratio to receive either ontunisertib at one of three dose levels, or a matching placebo, administered twice daily. The trial will consist of a 6-week screening period, a 52-week treatment period, and a 2-week follow-up period.

3/26 07:30

Agomab Granted U.S. Patent for AGMB-447

Agomab announced that the United States Patent and Trademark Office, or USPTO, has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5, currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis. This patent provides intellectual property protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始